

Cover Story
SWOG earlier this week started to accrue patients to Lung-MAP, a clinical trial for second-line treatment of non-small cell lung cancer.
By Tessa Vellek
In Brief


Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- CBER Director Vinay Prasad dared to “say no to drugs”
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”










